Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The GLP-1 receptor agonist exenatide is synthetic exendin-4, a peptide originally isolated from the salivary secretions of the Gila monster. Exenatide was developed as a first-in-class diabetes therapy, with immediate- and extended-release formulations. In preclinical diabetes models, exenatide enhanced glucose-dependent insulin secretion, suppressed inappropriately elevated glucagon secretion, slowed gastric emptying, reduced body weight, enhanced satiety, and preserved pancreatic β-cell function. In clinical trials, both exenatide formulations reduced hyperglycemia in patients with type 2 diabetes mellitus (T2DM) and were associated with weight loss. AREAS COVERED: This article reviews the development of exenatide from its discovery and preclinical investigations, to the elucidation of its pharmacological mechanisms of action in mammalian systems. The article also presents the pharmacokinetic profiling and toxicology studies of exenatide, as well as its validation in clinical trials. EXPERT OPINION: GLP-1 receptor agonists represent a new paradigm for the treatment of patients with T2DM. By leveraging incretin physiology, a natural regulatory system that coordinates oral nutrient intake with mechanisms of metabolic control, these agents address multiple core defects in the pathophysiology of T2DM. Studies have identified unique benefits including improvements in glycemic control and weight, and the potential for beneficial effects on the cardiometabolic system without the increased risk of hypoglycemia associated with insulin therapy. Peptide hormone therapeutics can offer significant advantages over small molecule drug targets when it comes to specificity, potency, and more predictable side effects. As exemplified by exenatide, injectable peptides can be important drugs for the treatment of chronic diseases, such as T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“2 GLP-1 and the GLP-1 receptor GLP-1 is rapidly secreted by the L-cells of the intestinal mucosa in response to nutrient ingestion directly into the hepatic portal circulation where a glucose sensor is located [11,13-19].”
BackgroundKieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 2×
“In hepatocytes, GLP-1 stimulated glycogen synthase a and this effect was blocked by the GLP-1 receptor antagonist exendin [9-39]amide.”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“The GLP-1 receptor was subsequently characterized as a seven-transmembrane domain, G-protein--coupled receptor with confirmed expression in pancreatic periductal and b-cells, kidney, heart, blood vessels, stomach, and brain [27-32].”
BackgroundResultEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 2×
“3 Adverse event surveillance issues The incidence of acute pancreatitis is rare in patients with T2DM (although elevated compared with the general population) whether or not they are being treated with exenatide or other diabetes drugs [103,104,109-111,125-127].”
Background
Research works printed but not linked: 101
- 10.1161/ATVBAHA.107.147538 · DOI · Paper page
- Göke R, 1993, Biol Chem, 268, 19650, 10.1016/S0021-9258(19)36565-2 · DOI · Paper page
- 10.1159/000194739 · DOI
- 10.2337/diacare.19.6.580 · DOI · Paper page
- 10.1016/j.mce.2008.08.012 · DOI · Paper page
- 10.1007/s001250050613 · DOI · Paper page
- Nauck MA, 1997, Am J Physiol, 273, E981
- 10.1055/s-2004-826161 · DOI
- 10.3109/9780203217412-17 · DOI
- Edvell A, 1999, Endocrin, 140, 778, 10.1210/endo.140.2.6514 · doi:10.1210/endo.140.2.6514 · Paper page
- 10.2337/diabetes.49.5.741 · DOI · Paper page
- 10.1146/annurev.med.57.110104.115624 · DOI · Paper page
- 10.1172/JCI119482 · DOI · Paper page
- 10.2337/diab.44.9.1126 · DOI · Paper page
- 10.1210/en.136.8.3585 · DOI · Paper page
- Raufman JP, 1992, J Biol Chem, 267, 21432, 10.1016/S0021-9258(19)36628-1 · DOI · Paper page
- 10.3109/10606820213687 · doi:10.3109/10606820213687 · Paper page
- 10.1016/j.regpep.2003.10.028 · DOI · Paper page
- 10.1210/endo.137.7.8770921 · DOI · Paper page
- Meloni AR, 2012, Diab Obes Metab
- 10.2337/diabetes.47.4.646 · DOI · Paper page
- 10.2337/diabetes.47.7.1046 · DOI · Paper page
- 10.2337/diabetes.47.4.632 · DOI · Paper page
- 10.2337/diabetes.48.10.1979 · DOI · Paper page
- 10.2337/diabetes.50.8.1720 · DOI · Paper page
- 10.2337/diabetes.52.2.365 · DOI · Paper page
- 10.3949/ccjm.76.s5.03 · DOI · Paper page
- 10.1074/jbc.272.7.4108 · DOI · Paper page
- 10.2337/diab.42.11.1678 · DOI · Paper page
- 10.1016/0167-0115(96)00135-8 · DOI
- 10.1016/0196-9781(94)90204-6 · DOI
- 10.1016/0922-4106(94)90085-X · DOI
- 10.1002/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L · DOI · Paper page
- 10.1016/S0165-1838(99)00086-7 · DOI
- Yang H, 1998, Am J Physiol, 273, C675, 10.1152/ajpcell.1998.275.3.C675 · DOI · Paper page
- 10.2337/diabetes.48.5.1026 · DOI · Paper page
- 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
- 10.1053/meta.2001.22519 · DOI · Paper page
- 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
- 10.1007/s001250051111 · DOI · Paper page
- Gedulin B, 1999, Diabetes, 48, A199
- 10.2337/diacare.24.2.371 · DOI · Paper page
- 10.1038/sj.ijo.0803284 · DOI
- 10.2337/diabetes.48.12.2270 · DOI · Paper page
- 10.2337/diabetes.50.7.1562 · DOI · Paper page
- 10.2337/diabetes.51.5.1443 · DOI · Paper page
- 10.1210/en.2004-1349 · DOI · Paper page
- 10.1002/ddr.1195 · DOI · Paper page
- Eng J, 1996, Diabetes, 45, 152A
- 10.1530/eje.0.1500097 · DOI · Paper page
- Parkes D, 2001, Diabetes, 50, A313
- 10.2337/diabetes.52.3.734 · DOI · Paper page
- 10.1152/ajpendo.00030.2002 · DOI · Paper page
- 10.1007/s00125-002-0828-3 · DOI · Paper page
- Jodka C, 1998, Diabetes, 47, A403
- Kinzig KP, 2002, J Neurosci, 22, 10470, 10.1523/JNEUROSCI.22-23-10470.2002 · DOI · Paper page
- Egan JM, 1994, Endocrinology, 135, 2070, 10.1210/endo.135.5.7956929 · doi:10.1210/endo.135.5.7956929 · Paper page
- 10.1677/jme.0.0190241 · DOI · Paper page
- 10.1089/met.2008.0095 · DOI · Paper page
- 10.1016/j.bbrc.2009.01.003 · DOI · Paper page
- 10.1186/1475-2840-9-32 · DOI · Paper page
- 10.1016/j.jacc.2008.10.033 · DOI · Paper page
- 10.1186/1475-2840-9-76 · DOI · Paper page
- 10.1007/s00125-009-1611-5 · DOI · Paper page
- 10.1111/j.1476-5381.2009.00486.x · DOI · Paper page
- 10.1124/jpet.300.3.958 · DOI · Paper page
- 10.1016/j.expneurol.2006.09.028 · DOI · Paper page
- 10.1371/journal.pone.0032008 · DOI · Paper page
- 10.2174/138920006776873490 · DOI · Paper page
- 10.1124/dmd.111.042291 · DOI
- 10.1152/ajpendo.00479.2010 · DOI · Paper page
- 10.2337/db09-0626 · DOI · Paper page
- Tatarkiewicz K, 2011, Diabetologia, 54, 185
- Bhavsar S, 2012, Curr Diab Rev
- 10.1016/j.clinthera.2012.04.013 · DOI · Paper page
- MacConell L, 2012, Diabetes Metab Syndr Obes, 5, 29
- MacConell L, 2012, Diabetes, 61, A598
- 10.3810/pgm.2010.05.2149 · DOI · Paper page
- 10.1089/dia.2011.0050 · DOI · Paper page
- 10.2337/dc10-0482 · DOI · Paper page
- 10.1111/j.1464-5491.2012.03652.x · DOI · Paper page
- 10.1111/j.1365-2125.2007.02890.x · DOI · Paper page
- 10.1038/ajh.2009.245 · DOI · Paper page
- 10.1093/eurheartj/ehr309 · DOI · Paper page
- 10.1161/CIRCINTERVENTIONS.112.968388 · DOI · Paper page
- 10.1210/jc.2011-3456 · DOI · Paper page
- 10.1007/s00125-011-2440-x · DOI
- 10.1210/jc.2003-032001 · DOI · Paper page
- 10.1530/EJE-11-0330 · DOI · Paper page
- 10.2337/dc11-0096 · DOI · Paper page
- Buse JB, 2012, Lancet
- 10.1111/j.1463-1326.2011.01533.x · DOI
- 10.1345/aph.1M676 · DOI · Paper page
- 10.1185/03007990902820519 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01376.x · DOI · Paper page
- Raufman JP, 1982, Am J Physiol, 242, G470
- 10.1046/j.1471-4159.1996.67051982.x · DOI · Paper page
- 10.1053/meta.2000.6251 · DOI
- 10.1055/s-2002-29087 · DOI · Paper page
- 10.1007/s00125-005-1795-2 · DOI
- 10.1016/j.ijpharm.2008.01.015 · DOI
Cited by
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Advances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
Self-citation
Metadata
- Authors
- Parkes, D. G., Mace, K. F., & Trautmann, M. E.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2012-12-12
- Volume
- 8
- Issue
- 2
- Pages
- 219-244
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2059228484
- Cited by
- 108
- References
- 30
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. https://app.cochat.ai/papers/10.1517/17460441.2013.741580
- The paper
- Parkes, D. G., Mace, K. F., & Trautmann, M. E. (2013). Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2013.741580
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.